[News] Personalised vaccine against acute myeloid leukaemia

A personalised cancer vaccine for acute myeloid leukaemia (AML) induces an immune response and protects against relapse, according to a new study. Jacalyn Rosenblatt (Beth Israel Deaconess Medical Center, Boston, MA, USA) and colleagues serially vaccinated 17 patients with AML who were in complete remission after undergoing chemotherapy. The median age of the patients was 63 years. After a median follow-up of 57 months, 12 patients remained in remission (71%; 90% CI 52 –89%).
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: News Source Type: research